Literature DB >> 3027389

Differential effects of acyclovir and 9-(1,3-dihydroxy-2-propoxymethyl)guanine on herpes simplex virus and Epstein-Barr virus in a dually infected human lymphoblastoid cell line.

C M van der Horst, J C Lin, N Raab-Traub, M C Smith, J S Pagano.   

Abstract

We investigated the effects of acyclovir and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) on a lymphoblastoid cell line dually infected with Epstein-Barr virus and herpes simplex virus (HSV) type 1. The numbers of Epstein-Barr virus genomes were reduced during 70 days of treatment with either drug. Both drugs suppressed HSV replication in a dose-related manner. In the continued presence of the drugs, HSV developed resistance, rapidly to acyclovir and much more slowly to 30 microM DHPG. Analysis of HSV glycoprotein C production and viral DNA showed that treatment with 100 microM DHPG eliminated HSV production, curing the cell line of HSV persistent infection.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3027389      PMCID： PMC253990          DOI： 10.1128/JVI.61.2.607-610.1987

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  23 in total

1.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

2.  Epstein-Barr virus-associated thymidine kinase.

Authors:  S T Chen; J E Estes; E S Huang; J S Pagano
Journal:  J Virol       Date:  1978-04       Impact factor: 5.103

3.  Characterization of an Epstein-Barr virus-induced thymidine kinase.

Authors:  M de Turenne-Tessier; T Ooka; G de The; J Daillie
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

4.  Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir.

Authors:  C S Crumpacker; L E Schnipper; S I Marlowe; P N Kowalsky; B J Hershey; M J Levin
Journal:  N Engl J Med       Date:  1982-02-11       Impact factor: 91.245

5.  Plaque autoradiography assay for the detection and quantitation of thymidine kinase-deficient and thymidine kinase-altered mutants of herpes simplex virus in clinical isolates.

Authors:  J L Martin; M N Ellis; P M Keller; K K Biron; S N Lehrman; D W Barry; P A Furman
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

6.  Acyclovir inhibition of Epstein-Barr virus replication.

Authors:  A K Datta; B M Colby; J E Shaw; J S Pagano
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

7.  Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci.

Authors:  L E Schnipper; C S Crumpacker
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

8.  In vitro and in vivo resistance of herpes simplex virus to 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine).

Authors:  K O Smith; W L Kennell; R H Poirier; F T Lynd
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

9.  Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1.

Authors:  D M Coen; P A Schaffer
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

10.  Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo.

Authors:  H J Field; G Darby
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191
View more
  2 in total

1.  Identification, expression, and immunogenicity of Kaposi's sarcoma-associated herpesvirus-encoded small viral capsid antigen.

Authors:  S F Lin; R Sun; L Heston; L Gradoville; D Shedd; K Haglund; M Rigsby; G Miller
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

Review 2.  Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections.

Authors:  D Faulds; R C Heel
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.